Herpes Simiae (B Virus) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
B virus, also known as Cercopithecine
herpesvirus 1, is an alphaherpesvirus commonly found in macaque monkeys. It is
the only non-human primate herpesvirus known to be highly pathogenic to humans
and can cause severe illness if left untreated. Human infection can occur
through a breach of the skin or mucosal defences, exposure to contaminated
fomites, or human-to-human transmission. The nasal mucosa is less ideal for
virus replication than the lung. The permissiveness of infection depends on the
initial site of virus exposure and the dose of virus introduced. Symptoms of B
virus infection in humans can range from a flu-like illness to neurological deterioration
and can appear days to years after exposure. The array of symptoms may depend
on the dose and route of inoculation and can culminate in respiratory failure.
Clinical progression is associated with consistent symptoms, including flu-like
illness, lymphadenitis, fever, headache, vomiting, myalgia, cramping, and
urinary retention with ascending paralysis.
·
Approximately 70% of untreated patients die of
complications associated with the infection. Since the B virus was identified
in 1932, only 50 people have been documented to have infections.
Thelansis’s “Herpes Simiae (B Virus)
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2021 To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Herpes Simiae (B Virus) treatment
modalities options for eight major markets (USA, Germany, France, Italy, Spain,
UK, Japan, and China).
KOLs insights
of Herpes Simiae (B Virus) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Herpes Simiae (B Virus) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment